Extension Study of Hetrombopag in Severe Aplastic Anemia

PHASE3Active, not recruitingINTERVENTIONAL

Enrollment

157

Participants

Timeline

Start Date

September 19, 2019

Primary Completion Date

November 30, 2024

Study Completion Date

December 31, 2024

Conditions

Treatment-naive Severe Aplastic Anemia

Interventions

DRUG

Hetrombopag Olamine

Hetrombopag Olamine; once daily

DRUG

Placebo

Placebo; once daily

Trial Locations (1)

Blood Diseases Hospital, Chinese Academy of Medical Sciences, Tianjin

All Listed Sponsors

lead

Jiangsu HengRui Medicine Co., Ltd.

INDUSTRY